Metabolic bioactivation and toxicity of ethyl 4-hydroxybenzoate in human SK-MEL-28 melanoma cells

Journal of Pharmaceutical Sciences

Volumn 97, Issue 5, 2008, Pages 1934-1945

  Vad, Nikhil M ^a   Shaik, Imam H ^a   Mehvar, Reza ^a   Moridani, Majid Y ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer; Ethyl 4 hydroxybenzoate; Melanoma; O quinone; SK MEL 28

Indexed keywords

1 BROMOHEPTANE; ASCORBIC ACID; CELL ENZYME; CYCLOSPORIN A; DICOUMAROL; DIHYDROLIPOAMIDE DEHYDROGENASE; ETHYL PARABEN; GLUTATHIONE; HEPTANE DERIVATIVE; MEQUINOL; MONOPHENOL MONOOXYGENASE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; 4 HYDROXYBENZOIC ACID ESTER; ETHYL-P-HYDROXYBENZOATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG METABOLISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; MALE; MELANOMA CELL; METABOLIC ACTIVATION; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL TOXICITY; NONHUMAN; RAT; TIME; ANIMAL; BIOTRANSFORMATION; MELANOMA; METABOLISM; PHYSIOLOGY; SOLUBILITY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; BIOTRANSFORMATION; CELL LINE, TUMOR; GLUTATHIONE; HUMANS; MALE; MELANOMA; MONOPHENOL MONOOXYGENASE; PARABENS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SOLUBILITY;

EID: 48549091040     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21107     Document Type: Article

References (31)

1. What are the key statistics about melanoma? [homepage on the Internet]. 2006. Bethesda: American Cancer Society. 03/09/2006 [cited January 28, 2007]. Available from http://www.cancer.org/docroot/ CRI/content/ CRI_2_4_lX_What_are_the_key_ statistics_for_melanoma_50.asp?sitearea=.
2. Saleh F, Renno W, Klepacek I, Ibrahim G, Asfar S, Dashti H, Romero P, Dashti A, Behbehani A. 2005. Melanoma immunotherapy: Past, present, and future. Curr Pharm Des 11:3461-3473.
3. Grossman D, Altieri DC. 2001. Drug resistance in melanoma: Mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20:3-11.
4. Anderson CM, Buzaid AC, Legha SS. 1995. Systemic treatments for advanced cutaneous melanoma. Oncology (Williston Park) 9:1149-1158.
5. Moridani MY, Moore M, Bartsch RA, Yang Y, Heibati-Sadati S. 2005. Structural toxicity relationship of 4-alkoxyphenols' cytotoxicity towards murine B16-F0 melanoma cell line. J Pharm Pharm Sci 8:348-360.
6. Riley PA. 1969. Hydroxyanisole depigmentation: In-vitro studies. J Pathol 97:193-206.
7. Naish S, Cooksey CJ, Riley PA. 1988. Initial mushroom tyrosinase-catalysed oxidation product of 4-hydroxyanisole is 4-methoxy-ortho-benzoquinone. Pigment Cell Res 1:379-381.
8. Naish S, Holden JL, Cooksey CJ, Riley PA. 1988. Major primary cytotoxic product of 4-hydroxyanisole oxidation by mushroom tyrosinase is 4-methoxy ortho benzoquinone. Pigment Cell Res 1:382-385.
9. Moridani MY, Cheon SS, Khan S, O'Brien PJ. 2002. Metabolic activation of 4-hydroxyanisole by isolated rat hepatocytes. Drug Metab Dispos 10:1063-1069.
10. Land EJ, Cooksey CJ, Riley PA. 1990. Reaction kinetics of 4-methoxy ortho benzoquinone in relation to its mechanism of cytotoxicity: A pulse radi-olysis study. Biochem Pharmacol 39:1133-1135.
11. Morgan BDG. 1984. Recent results of a clinical pilot study of intra-arterial 4-hydroxyanisole chemothr-apy in malignant melanoma. In: Riley PA, editor. Hydroxyanisole: Recent advances in anti-melanoma therapy. England: IRL Press Limited, pp 233-241.
12. Moridani MY. 2006. Biochemical basis of 4-hydroxyanisole induced cell toxicity towards B 16-F0 melanoma cells. Cancer Lett 243:235-245.
13. Ellman GL. 1959. Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77.
14. Gergel' D, Cederbaum AI. 1997. Interaction of nitric oxide with 2-thio-5-nitrobenzoic acid: Implications for the determination of free sulfhydryl groups by ellman's reagent. Arch Biochem Biophys 347:282-288.
15. Krikun G, Cederbaum AI. 1984. Increased microsomal oxidation of alcohols after pyrazole treatment and its similarities to the induction by ethanol consumption. Biochim Biophys Acta 801:131-137.
16. Dallner G. 1978. Isolation of microsomal subfractions by use of density gradients. Methods Enzymol 52:71-82.
17. Kruger NJ. 1994. The Bradford method for protein quantitation. Methods Mol Biol 32:9-15.
18. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M, Gao X, Xu Q. 2004. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol 164: 2039-2054.
19. Moridani MY, Cheon SS, Khan S, O'Brien PJ. 2003. Metabolic activation of 3-hydroxyanisole by isolated rat hepatocytes. Chem Biol Interact 142: 317-333.
20. Shaik IH, Mehvar R. 2006. Rapid determination of reduced and oxidized glutathione levels using a new thiol-masking reagent and the enzymatic recycling method: Application to the rat liver and bile samples. Anal Bioanal Chem 385:105-113.
21. Siraki AG, Chan TS, O'Brien PJ. 2004. Application of quantitative structure-toxicity relationships for the comparison of the cytotoxicity of 14 p-benzoquinone congeners in primary cultured rat hepatocytes versus PC12 cells. Toxicol Sci 81:148-159.
22. Preusch PC, Siegel D, Gibson NW, Ross D. 1991. A note on the inhibition of DT-diaphorase by dicou-marol. Free Radic Biol Med 11:77-80.
23. Khan S, O'Brien PJ. 1991. 1-Bromoalkanes as new potent nontoxic glutathione depletors in isolated rat hepatocytes. Biochem Biophys Res Commun 179:436-441.
24. Broekemeier KM, Pfeiffer DR. 1989. Cyclosporin A-sensitive and insensitive mechanisms produce the permeability transition in mitochondria. Biochem Biophys Res Commun 163:561-566.
25. Rustin GJ, Stratford MR, Lamont A, Bleehen N, Philip PA, Howells N, Watfa RR, Slack JA. 1992. Phase I study of intravenous 4-hydroxyanisole. Eur J Cancer 28A:1362-1364.
26. Swinney R, Hsu S, Tomlinson G. 2006. Phase I and Phase II enzyme polymorphisms and childhood cancer. J Investig Med 54:303-320.
27. Anasagasti MJ, Martin JJ, Mendoza L, Obrador E, Estrela JM, McCuskey RS, Vidal-Vanaclocha F. 1998. Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature. Hepatology 27:1249-1256.
28. Nakagawa Y, Moore G. 1999. Role of mitochondrial membrane permeability transition in p-hydroxy-benzoate ester-induced cytotoxicity in rat hepatocytes. Biochem Pharmacol 58:811-816.
29. Skulachev VP. 1996. Why are mitochondria involved in apoptosis? Permeability transition pores and apoptosis as selective mechanisms to eliminate superoxide-producing mitochondria and cell. FEBS Lett 397:7-10.
30. Lash LH. 2006. Mitochondrial glutathione transport: Physiological, pathological and toxicological implications. Chem Biol Interact 163:54-67.
31. Kovacic P, Pozos RS, Somanathan R, Shangari N, O'Brien PJ. 2005. Mechanism of mitochondrial un-couplers, inhibitors, and toxins: Focus on electron transfer, free radicals, and structure-activity relationships. Curr Med Chem 12:2601-2623.